

Amendments to the Claims:

Please amend claims 5, 9-10 and 20. This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Withdrawn) A nonapeptide selected from the group of peptides comprising the amino acid sequence of SEQ ID NO: 2, 3, 5, 8, 11, and 12 or a peptide with cytotoxic T cell inducibility, wherein one, two, or more amino acids have been substituted or added to the amino acid sequence of SEQ ID NO: 2, 3, 5, 8, 11, or 12.
2. (Cancelled)
3. (Withdrawn) The peptide of claim 1, wherein the second amino acid from the N terminus is phenylalanine, tyrosine, methionine, or tryptophan.
4. (Withdrawn) The peptide of claim 1 or 3, wherein the C-terminal amino acid is phenylalanine, leucine, isoleucine, tryptophan, or methionine.
5. (Currently Amended) An isolated nonapeptide or decapeptide consisting of a peptide having an amino acid sequence selected from the group of ~~peptides comprising~~ consisting of the amino acid sequence of SEQ ID NO: 29, 30, 33, 34, 40, and 46 or a peptide with cytotoxic T cell inducibility, wherein one~~[[,]]~~ or two, ~~or more~~ amino acids have been substituted or added to the amino acid sequence of SEQ ID NO: 29, 30, 33, 34, 40, or 46.
6. (Cancelled)
7. (Previously Presented) The peptide of claim 5, wherein the second amino acid from the N terminus is leucine or methionine.

8. (Previously Presented) The peptide of claim 5 or 7, wherein the C-terminal amino acid is valine or leucine.
9. (Currently Amended) A pharmaceutical composition for treating and/or preventing tumors, wherein the pharmaceutical comprises one or more peptides of claim ~~4~~ or 5.
10. (Currently Amended) A pharmaceutical composition for treating diabetic retinopathy, chronic rheumatoid arthritis, psoriasis, and atherosclerosis, wherein the pharmaceutical comprises one or more peptides of claim ~~4~~ or 5.
11. (Withdrawn) An exosome that presents on its surface a complex comprising a peptide of claim 1 or 5, and an HLA antigen.
12. (Withdrawn) The exosome of claim 11, wherein the HLA antigen is HLA-A24 or HLA-A02.
13. (Withdrawn) The exosome of claim 12, wherein the HLA antigen is HLA-A2402 or HLA-0201.
14. (Withdrawn) A method for inducing an antigen-presenting cell with high cytotoxic T cell inducibility by using a peptide of claim 1 or 5.
15. (Withdrawn) A method for inducing a cytotoxic T cell by using a peptide of claim 1 or 5.
16. (Withdrawn) A method for inducing an antigen-presenting cell with high cytotoxic T cell inducibility, wherein said method comprises the step of introducing a gene that comprises a polynucleotide encoding a peptide of claim 1 or 5 into an antigen-presenting cell.
17. (Withdrawn) An isolated cytotoxic T cell that is induced by using a peptide of claim 1 or 5.

18. (Withdrawn) An antigen-presenting cell that presents a complex of an HLA antigen and a peptide of claim 1 or 5.
19. (Withdrawn) The antigen-presenting cell induced by the method of claim 14.
20. (Currently Amended) A vaccine for inhibiting angiogenesis at a diseased site, wherein the vaccine comprises a peptide of claim ~~1-5~~ 5 as an active ingredient.
21. (Original) The vaccine of claim 20, which is used for administration to a subject whose HLA antigen is HLA-A24 or HLA-A02.
22. (Previously Presented) The vaccine of claim 20, which is used to suppress the growth and/or metastasis of malignant tumors.
23. (New) The peptide of claim 5, wherein said peptide has an amino acid sequence as set forth in SEQ ID NO:54.